|
PT2173888T
(pt)
*
|
2007-07-26 |
2016-11-17 |
Uniqure Ip Bv |
Resumo
|
|
GB0911870D0
(en)
|
2009-07-08 |
2009-08-19 |
Ucl Business Plc |
Optimised coding sequence and promoter
|
|
US9228174B2
(en)
*
|
2010-03-11 |
2016-01-05 |
Uniqure Ip B.V. |
Mutated rep encoding sequences for use in AAV production
|
|
WO2011122950A1
(en)
|
2010-04-01 |
2011-10-06 |
Amsterdam Molecular Therapeutics (Amt) Ip B.V. |
Monomeric duplex aav vectors
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
WO2012145509A2
(en)
|
2011-04-19 |
2012-10-26 |
The Research Foundation Of State University Of New York |
Adeno-associated-virus rep sequences, vectors, and viruses
|
|
GB201210357D0
(en)
|
2012-06-12 |
2012-07-25 |
Ucl Business Plc |
Factor VIII sequences
|
|
WO2015060722A1
(en)
|
2013-10-24 |
2015-04-30 |
Uniqure Ip B.V. |
Aav-5 pseudotyped vector for gene therapy for neurological diseases
|
|
ES2990174T3
(es)
|
2014-03-10 |
2024-11-29 |
Uniqure Ip Bv |
Vectores de AAV mejorados producidos en células de insecto
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
KR20170096998A
(ko)
|
2014-11-05 |
2017-08-25 |
보이저 테라퓨틱스, 인크. |
파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
WO2016077689A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
DK3224376T4
(da)
|
2014-11-28 |
2023-05-30 |
Uniqure Ip Bv |
DNA-forureninger i en sammensætning omfattende en parvoviral virion
|
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
EA037696B1
(ru)
|
2014-12-24 |
2021-05-12 |
ЮНИКЕР АйПи Б.В. |
Супрессия гена гентингтина, индуцированная рнк-интерференцией
|
|
JP7496667B2
(ja)
*
|
2016-04-21 |
2024-06-07 |
ビロベク，インコーポレイテッド |
昆虫細胞中でのａａｖ生成、方法およびその組成物
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
CA3024448C
(en)
|
2016-05-18 |
2025-09-09 |
Voyager Therapeutics, Inc. |
MODULATING POLYNUCLEOTIDES
|
|
BR112018073472A2
(pt)
|
2016-05-18 |
2019-08-27 |
Voyager Therapeutics Inc |
composições e métodos de tratamento da doença de huntington
|
|
EP3491008A2
(en)
*
|
2016-07-26 |
2019-06-05 |
BioMarin Pharmaceutical Inc. |
Novel adeno-associated virus capsid proteins
|
|
EP3510161A4
(en)
|
2016-08-23 |
2020-04-22 |
Akouos, Inc. |
COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
|
|
JP2019531787A
(ja)
|
2016-08-30 |
2019-11-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
|
|
CA3045551A1
(en)
|
2016-12-16 |
2018-06-21 |
Uniqure Ip B.V. |
Immunoadsorption
|
|
WO2018204786A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
SG11201909868YA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
IL271957B2
(en)
|
2017-07-10 |
2024-02-01 |
Uniqure Ip Bv |
Means and methods for AAV-based gene therapy
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
EP3662060A2
(en)
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CA3075656A1
(en)
|
2017-09-29 |
2019-04-04 |
Voyager Therapeutics, Inc. |
Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
WO2019079240A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
CN111527201A
(zh)
|
2017-12-29 |
2020-08-11 |
优尼科Ip有限公司 |
修饰的病毒载体及其制备和使用方法
|
|
LT3740222T
(lt)
|
2018-01-17 |
2023-09-11 |
Meiragtx Uk Ii Limited |
Modifikuotas raav kapsidės baltymas, skirtas genų terapijai
|
|
GB201800903D0
(en)
|
2018-01-19 |
2018-03-07 |
Oxford Genetics Ltd |
Vectors
|
|
JP2021523914A
(ja)
|
2018-05-15 |
2021-09-09 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
パーキンソン病を治療するための組成物および方法
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
US12060567B2
(en)
|
2018-06-13 |
2024-08-13 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (UTR) for AAV production
|
|
JP7565218B2
(ja)
|
2018-07-02 |
2024-10-10 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症および脊髄に関連する障害の治療
|
|
US20210355454A1
(en)
|
2018-07-24 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
GB201813528D0
(en)
|
2018-08-20 |
2018-10-03 |
Ucl Business Plc |
Factor IX encoding nucleotides
|
|
US10842885B2
(en)
|
2018-08-20 |
2020-11-24 |
Ucl Business Ltd |
Factor IX encoding nucleotides
|
|
CA3112007A1
(en)
|
2018-09-12 |
2020-03-19 |
Uniqure Ip B.V. |
Rnai induced c9orf72 suppression for the treatment of als/ftd
|
|
WO2020061418A1
(en)
*
|
2018-09-20 |
2020-03-26 |
Tallgrass Biologics L.L.C. |
Treatment and control of colony collapse disorder
|
|
CN109295172A
(zh)
*
|
2018-09-26 |
2019-02-01 |
浙江海洋大学 |
大黄鱼清道夫受体家族基因的密码子偏好性分析方法
|
|
JP7528066B2
(ja)
|
2018-09-28 |
2024-08-05 |
ボイジャー セラピューティクス インコーポレイテッド |
操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
|
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
AU2019354793A1
(en)
|
2018-10-05 |
2021-05-13 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding AAV production proteins
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3867389A1
(en)
|
2018-10-15 |
2021-08-25 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
|
EP3884050A1
(en)
|
2018-11-19 |
2021-09-29 |
uniQure IP B.V. |
Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3
|
|
WO2020104435A1
(en)
|
2018-11-19 |
2020-05-28 |
Uniqure Ip B.V. |
A companion diagnostic to monitor the effects of gene therapy
|
|
WO2020104480A1
(en)
|
2018-11-19 |
2020-05-28 |
Uniqure Biopharma B.V. |
Adeno-associated virus vectors for expressing fviii mimetics and uses thereof
|
|
AU2019382824A1
(en)
|
2018-11-19 |
2021-06-03 |
Uniqure Ip B.V. |
Method and means to deliver miRNA to target cells
|
|
US20220064671A1
(en)
|
2019-01-18 |
2022-03-03 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
EP3962536A1
(en)
|
2019-04-29 |
2022-03-09 |
Voyager Therapeutics, Inc. |
Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
|
|
CA3146791A1
(en)
|
2019-07-15 |
2021-01-21 |
Meiragtx Uk Ii Limited |
Modified aav capsid proteins for treatment of arthritic disease
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
TW202122582A
(zh)
|
2019-08-26 |
2021-06-16 |
美商航海家醫療公司 |
病毒蛋白之控制表現
|
|
WO2021041375A1
(en)
*
|
2019-08-26 |
2021-03-04 |
Rootpath Genomics, Inc. |
Compositions and methods for producing adeno-associated viral vectors
|
|
WO2021053018A1
(en)
|
2019-09-16 |
2021-03-25 |
Uniqure Ip B.V. |
Targeting misspliced transcripts in genetic disorders
|
|
WO2021113767A1
(en)
*
|
2019-12-04 |
2021-06-10 |
Sangamo Therapeutics, Inc. |
Novel compositions and methods for producing recombinant aav
|
|
BR112022016596A2
(pt)
|
2020-02-21 |
2022-11-16 |
Akouos Inc |
Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano
|
|
WO2021195491A2
(en)
*
|
2020-03-26 |
2021-09-30 |
Asklepios Biopharmaceutical, Inc. |
Inducible promoter for viral vector production
|
|
EP4127146A1
(en)
|
2020-04-02 |
2023-02-08 |
uniQure biopharma B.V. |
Novel cell line
|
|
CA3169087A1
(en)
*
|
2020-04-02 |
2021-10-07 |
David Johannes Francois DU PLESSIS |
Dual bifunctional vectors for aav production
|
|
WO2021204872A1
(en)
|
2020-04-07 |
2021-10-14 |
Uniqure Ip B.V. |
Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof
|
|
WO2021211753A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
EP4189095A1
(en)
|
2020-07-27 |
2023-06-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
EP4305157A1
(en)
|
2021-03-09 |
2024-01-17 |
Huidagene Therapeutics (Singapore) Pte. Ltd. |
Engineered crispr/cas13 system and uses thereof
|
|
WO2022214635A1
(en)
|
2021-04-08 |
2022-10-13 |
Stichting Vu |
Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
|
|
AU2022285138A1
(en)
|
2021-06-02 |
2023-11-30 |
Uniqure Biopharma B.V. |
Adeno-associated virus vectors modified to bind high-density lipoprotein
|
|
WO2022253955A2
(en)
|
2021-06-02 |
2022-12-08 |
Uniqure Biopharma B.V. |
Insect cell production of parvoviral vectors with modified capsid proteins
|
|
US20250382611A1
(en)
|
2021-06-21 |
2025-12-18 |
Uniqure Biopharma B.V. |
Gene constructs for silencing alpha-synuclein and uses thereof
|
|
CN117836010A
(zh)
|
2021-06-21 |
2024-04-05 |
优尼科生物制药有限公司 |
改进的裂解程序
|
|
WO2023283962A1
(en)
|
2021-07-16 |
2023-01-19 |
Huigene Therapeutics Co., Ltd. |
Modified aav capsid for gene therapy and methods thereof
|
|
AU2022317647A1
(en)
*
|
2021-07-28 |
2024-01-25 |
Biomarin Pharmaceutical Inc. |
Large scale adeno-associated virus production systems
|
|
EP4392434A1
(en)
|
2021-08-26 |
2024-07-03 |
uniQure biopharma B.V. |
Insect cell-produced high potency aav vectors with cns-tropism
|
|
WO2023091949A2
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4469585A2
(en)
|
2022-01-25 |
2024-12-04 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
CN114703203B
(zh)
*
|
2022-02-11 |
2024-08-06 |
上海渤因生物科技有限公司 |
杆状病毒载体及其用途
|
|
JP2025513066A
(ja)
|
2022-04-12 |
2025-04-22 |
ユニキュアー バイオファーマ ビー．ブイ． |
Ａｐｏｅの核酸制御
|
|
US20250297252A1
(en)
|
2022-04-12 |
2025-09-25 |
Uniqure Biopharma B.V. |
Nucleic acid regulation of SNCA
|
|
US20250230437A1
(en)
|
2022-04-12 |
2025-07-17 |
Uniqure Biopharma B.V. |
Novel systems for nucleic acid regulation
|
|
WO2023198702A1
(en)
|
2022-04-12 |
2023-10-19 |
Uniqure Biopharma B.V. |
Nucleic acid regulation of c9orf72
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2024143440A1
(ja)
|
2022-12-28 |
2024-07-04 |
富士フイルム株式会社 |
アデノ随伴ウイルスの製造方法、およびベクターのセット
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024218192A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
|
|
WO2024218190A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Generation of adeno-associated virus capsid libraries for insect cells
|
|
AU2024256392A1
(en)
|
2023-04-18 |
2025-10-23 |
Uniqure Biopharma B.V. |
Gene delivery vehicles comprising rna and antibodies
|
|
WO2024226761A2
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2024261220A1
(en)
|
2023-06-23 |
2024-12-26 |
Uniqure Biopharma B.V. |
Novel fragile x constructs
|
|
WO2025049993A1
(en)
|
2023-08-31 |
2025-03-06 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2025051805A1
(en)
|
2023-09-04 |
2025-03-13 |
Uniqure Biopharma B.V. |
Novel neurotropic recombinant adeno-associated virus particles
|
|
WO2025078606A1
(en)
|
2023-10-11 |
2025-04-17 |
Uniqure Biopharma B.V. |
Further novel systems for nucleic acid regulation
|
|
WO2025078598A1
(en)
|
2023-10-11 |
2025-04-17 |
Uniqure Biopharma B.V. |
Novel nucleic acid regulation of huntingtin gene
|
|
WO2025078602A1
(en)
|
2023-10-11 |
2025-04-17 |
Uniqure Biopharma B.V. |
Nucleic acid regulation of msh3 in repeat expansion disorders
|
|
WO2025114524A1
(en)
|
2023-11-30 |
2025-06-05 |
Uniqure Biopharma B.V. |
Formulations for viral drug products
|
|
WO2025171227A1
(en)
|
2024-02-08 |
2025-08-14 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2025219443A1
(en)
|
2024-04-19 |
2025-10-23 |
Uniqure Biopharma B.V. |
Nucleic acid for a1at regulation
|